Fu Jennifer, Tomlinson George, Feig Denice S
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
University Health Network, Toronto, Ontario, Canada.
Diabetes Metab Res Rev. 2021 Nov;37(8):e3453. doi: 10.1002/dmrr.3453. Epub 2021 Apr 13.
To evaluate the risk of adverse fetal outcomes after exposure to angiotensin converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) in first trimester of pregnancy, by conducting a systematic review and meta-analysis.
A systematic literature search was conducted using Medline, Embase, Cochrane and PubMed from inception to 25 November 2019. Studies were included if they evaluated pregnancies exposed to ACE-Is or ARBs, reported fetal outcomes, and compared these outcomes with a control group. Pooled odds ratios (ORs) were estimated using inverse variance-weighted random effects model. The protocol was registered with the PROSPERO International Prospective Register of Systematic Reviews (CRD42020160566).
Studies reporting on 6234 pregnancies exposed to ACE-Is or ARBs, 4104 pregnancies exposed to other oral antihypertensives, and 1,872,733 pregnancies without exposure were included in the meta-analysis. ACE-I or ARB exposed pregnancies, compared to non-exposed controls, had higher risk of major congenital malformations (OR 1.82; 95% confidence interval [CI]: 1.42-2.34), cardiovascular malformations (OR 2.50; 95% CI: 1.62-3.87) and stillbirths (OR 1.75; 95% CI: 1.21-2.53). There was no difference in congenital malformations observed between pregnancies exposed to other antihypertensives compared to non-exposed controls (OR 0.96; 95% CI: 0.69-1.33).
Women exposed to ACE-Is or ARBs during early pregnancy had higher risk of adverse fetal outcomes, including malformations and stillbirths, than non-exposed controls. This increased risk was independent of underlying maternal hypertension, as those exposed to other antihypertensives did not exhibit a higher risk than healthy controls. Women planning for pregnancy using these medications, including those with diabetic nephropathy, should be counselled appropriately.
通过进行系统评价和荟萃分析,评估妊娠早期接触血管紧张素转换酶抑制剂(ACE-Is)或血管紧张素受体阻滞剂(ARBs)后不良胎儿结局的风险。
使用Medline、Embase、Cochrane和PubMed从数据库建立至2019年11月25日进行系统文献检索。纳入的研究需评估接触ACE-Is或ARBs的妊娠情况,报告胎儿结局,并将这些结局与对照组进行比较。采用逆方差加权随机效应模型估计合并比值比(ORs)。该方案已在国际前瞻性系统评价注册库PROSPERO(CRD42020160566)注册。
荟萃分析纳入了报告6234例接触ACE-Is或ARBs的妊娠、4104例接触其他口服抗高血压药物的妊娠以及1,872,733例未接触药物的妊娠的研究。与未接触的对照组相比,接触ACE-I或ARB的妊娠出现重大先天性畸形(OR 1.82;95%置信区间[CI]:1.42 - 2.34)、心血管畸形(OR 2.50;95% CI:1.62 - 3.87)和死产(OR 1.75;95% CI:1.21 - 2.53)的风险更高。与未接触的对照组相比,接触其他抗高血压药物妊娠的先天性畸形情况无差异(OR 0.96;95% CI:0.69 - 1.33)。
与未接触的对照组相比,妊娠早期接触ACE-Is或ARBs的女性出现不良胎儿结局(包括畸形和死产)的风险更高。这种风险增加与潜在的母亲高血压无关,因为接触其他抗高血压药物的女性未表现出比健康对照组更高的风险。对于计划使用这些药物妊娠的女性,包括患有糖尿病肾病的女性,应给予适当的咨询。